Becton, Dickinson and Company (NYSE:BDX) Given New $200.00 Price Target at Bank of America

Becton, Dickinson and Company (NYSE:BDX) had its target price hoisted by stock analysts at Bank of America from $185.00 to $200.00 in a note issued to investors on Monday,Benzinga reports. The firm presently has a “neutral” rating on the medical instruments supplier’s stock. Bank of America‘s target price would indicate a potential upside of 6.36% from the company’s previous close.

BDX has been the subject of a number of other reports. Royal Bank Of Canada lifted their target price on Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a “sector perform” rating in a research report on Thursday, August 13th. Citigroup reiterated a “buy” rating on shares of Becton, Dickinson and Company in a report on Thursday, August 13th. Evercore set a $180.00 price objective on Becton, Dickinson and Company in a research note on Monday, July 6th. Jefferies Financial Group reiterated a “buy” rating and issued a $210.00 target price on shares of Becton, Dickinson and Company in a report on Thursday, August 6th. Finally, UBS Group assumed coverage on shares of Becton, Dickinson and Company in a research report on Tuesday, July 28th. They set a “buy” rating and a $190.00 price target for the company. Eight equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Becton, Dickinson and Company presently has an average rating of “Hold” and an average target price of $187.67.

Becton, Dickinson and Company Trading Down 0.8%

Shares of NYSE:BDX traded down $1.48 on Monday, hitting $188.04. 653,609 shares of the company’s stock were exchanged, compared to its average volume of 2,605,890. The business’s 50 day simple moving average is $166.14 and its two-hundred day simple moving average is $160.20. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51. The stock has a market capitalization of $51.81 billion, a price-to-earnings ratio of 56.64, a price-to-earnings-growth ratio of 13.36 and a beta of 0.19. Becton, Dickinson and Company has a 12 month low of $127.59 and a 12 month high of $193.07.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.14 by $0.09. The company had revenue of $4.98 billion during the quarter, compared to analysts’ expectations of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The firm’s quarterly revenue was up 5.4% on a year-over-year basis. During the same period in the previous year, the company earned $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Analysts anticipate that Becton, Dickinson and Company will post 12.67 EPS for the current fiscal year.

Insider Buying and Selling

In other Becton, Dickinson and Company news, EVP Roland Goette sold 2,438 shares of the firm’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total value of $440,887.92. Following the transaction, the executive vice president directly owned 14,856 shares of the company’s stock, valued at $2,686,559.04. This trade represents a 14.10% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Thomas E. Polen, Jr. sold 4,152 shares of the company’s stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $185.00, for a total value of $768,120.00. Following the completion of the transaction, the chief executive officer owned 110,163 shares in the company, valued at $20,380,155. This represents a 3.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 9,105 shares of company stock valued at $1,590,208 over the last quarter. 0.40% of the stock is currently owned by company insiders.

Institutional Trading of Becton, Dickinson and Company

A number of institutional investors have recently bought and sold shares of BDX. Amundi raised its position in shares of Becton, Dickinson and Company by 11.4% during the 2nd quarter. Amundi now owns 1,816,703 shares of the medical instruments supplier’s stock worth $274,922,000 after acquiring an additional 186,541 shares in the last quarter. First Eagle Investment Management LLC increased its stake in Becton, Dickinson and Company by 15.8% in the second quarter. First Eagle Investment Management LLC now owns 13,815,335 shares of the medical instruments supplier’s stock valued at $2,090,675,000 after purchasing an additional 1,887,224 shares during the last quarter. California State Teachers Retirement System raised its holdings in Becton, Dickinson and Company by 14,668.6% during the second quarter. California State Teachers Retirement System now owns 69,907,953 shares of the medical instruments supplier’s stock worth $10,579,171,000 after purchasing an additional 69,434,598 shares in the last quarter. Studio Investment Management LLC lifted its position in shares of Becton, Dickinson and Company by 11.2% during the 2nd quarter. Studio Investment Management LLC now owns 11,872 shares of the medical instruments supplier’s stock worth $1,797,000 after buying an additional 1,193 shares during the last quarter. Finally, Wedmont Private Capital purchased a new stake in shares of Becton, Dickinson and Company during the 2nd quarter worth approximately $206,000. 86.97% of the stock is owned by hedge funds and other institutional investors.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.